Cardiovascular safety of obesity treatment naltrexone-bupropion uncertain
Tuesday, March 8, 2016 - 15:30
in Health & Medicine
The cardiovascular safety of the obesity treatment naltrexone-bupropion remains uncertain because of the unanticipated early termination of a trial to determine its safety, according to a study.